163 related articles for article (PubMed ID: 38072134)
1. Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.
Alqazzaz MA; Luciani GM; Vu V; Machado RAC; Szewczyk MM; Adamson EC; Cheon S; Li F; Arrowsmith CH; Minden MD; Barsyte-Lovejoy D
Exp Hematol; 2024 Feb; 130():104135. PubMed ID: 38072134
[TBL] [Abstract][Full Text] [Related]
2. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
[TBL] [Abstract][Full Text] [Related]
3. Disruption of FOXP3-EZH2 Interaction Represents a Pathobiological Mechanism in Intestinal Inflammation.
Bamidele AO; Svingen PA; Sagstetter MR; Sarmento OF; Gonzalez M; Braga Neto MB; Kugathasan S; Lomberk G; Urrutia RA; Faubion WA
Cell Mol Gastroenterol Hepatol; 2019; 7(1):55-71. PubMed ID: 30510991
[TBL] [Abstract][Full Text] [Related]
4. Polycomb Repressive Complex 2 in Oncology.
Guo Y; Yu Y; Wang GG
Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
[TBL] [Abstract][Full Text] [Related]
5. Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures.
Aldana J; Gardner ML; Freitas MA
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511137
[TBL] [Abstract][Full Text] [Related]
6. Drug addiction unveils a repressive methylation ceiling in EZH2-mutant lymphoma.
Kwok HS; Freedy AM; Siegenfeld AP; Morriss JW; Waterbury AL; Kissler SM; Liau BB
Nat Chem Biol; 2023 Sep; 19(9):1105-1115. PubMed ID: 36973442
[TBL] [Abstract][Full Text] [Related]
7. Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma.
Cheng Y; Song Z; Fang X; Tang Z
Clin Epigenetics; 2024 Apr; 16(1):54. PubMed ID: 38600608
[TBL] [Abstract][Full Text] [Related]
8. JARID2 and EZH2, the eminent epigenetic drivers in human cancer.
Sreeshma B; Devi A
Gene; 2023 Aug; 879():147584. PubMed ID: 37353042
[TBL] [Abstract][Full Text] [Related]
9. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer.
Chandnani N; Gupta I; Thakkar V; Sarkar K
Pathol Res Pract; 2023 Nov; 251():154885. PubMed ID: 37862922
[TBL] [Abstract][Full Text] [Related]
11. Point mutations in the WD40 domain of Eed block its interaction with Ezh2.
Denisenko O; Shnyreva M; Suzuki H; Bomsztyk K
Mol Cell Biol; 1998 Oct; 18(10):5634-42. PubMed ID: 9742080
[TBL] [Abstract][Full Text] [Related]
12. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
13. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
14. MAPRE3 as an epigenetic target of EZH2 restricts ovarian cancer proliferation in vitro and in vivo.
Zhang Y; Liu F; Zheng J; Jiang K; Ai H; Liu L; Mao D
Exp Cell Res; 2024 Feb; 435(1):113913. PubMed ID: 38199479
[TBL] [Abstract][Full Text] [Related]
15. Stage-specific dual function: EZH2 regulates human erythropoiesis by eliciting histone and non-histone methylation.
Li M; Liu D; Xue F; Zhang H; Yang Q; Sun L; Qu X; Wu X; Zhao H; Liu J; Kang Q; Wang T; An X; Chen L
Haematologica; 2023 Sep; 108(9):2487-2502. PubMed ID: 37021526
[TBL] [Abstract][Full Text] [Related]
16. The EZH2-PRC2-H3K27me3 axis governs the endometrial cell cycle and differentiation for blastocyst invasion.
Fukui Y; Hirota Y; Aikawa S; Sakashita A; Shimizu-Hirota R; Takeda N; Ishizawa C; Iida R; Kaku T; Hirata T; Hiraoka T; Akaeda S; Matsuo M; Osuga Y
Cell Death Dis; 2023 May; 14(5):320. PubMed ID: 37198149
[TBL] [Abstract][Full Text] [Related]
17. Unlocking adult T-cell leukemia/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1/2 inhibition.
Tavakoli Shirazi P; Bywater MJ
Immunol Cell Biol; 2024; 102(5):298-301. PubMed ID: 38606590
[TBL] [Abstract][Full Text] [Related]
18. EZH2 in Myeloid Malignancies.
Rinke J; Chase A; Cross NCP; Hochhaus A; Ernst T
Cells; 2020 Jul; 9(7):. PubMed ID: 32650416
[TBL] [Abstract][Full Text] [Related]
19. Role of EZH2 in adipogenesis and obesity: Current state of the art and implications - A review.
Wang H
Medicine (Baltimore); 2022 Sep; 101(36):e30344. PubMed ID: 36086687
[TBL] [Abstract][Full Text] [Related]
20. Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of
Demosthenous C; Gupta SK; Sun J; Wang Y; Troska TP; Gupta M
Front Oncol; 2020; 10():1226. PubMed ID: 32850364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]